Lipocine Investor Relations Material
Latest events
Status Update
Lipocine
Q1 2025
27 Aug, 2025
Q2 2025
5 Aug, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lipocine Inc
Access all reports
Lipocine Inc. is a biopharmaceutical company focused on the development of oral drug delivery technologies for treating metabolic and endocrine disorders. The company specializes in hormone therapeutics, leveraging its proprietary Liprocol technology to enhance drug absorption and bioavailability. Lipocine's pipeline includes treatments for conditions such as testosterone deficiency, liver disease, and neuroendocrine disorders. The company is headquartered in Salt Lake City, Utah, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
LPCN
Country
🇺🇸 United States